Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.55 |
| ▸ | LIPE | Q05469 | 5/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | IDH1 | O75874 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147161 | 0.89 | CHRNB2 (0.51) | EPHX2LIPETP53EPHX1MAPT | |
| SCHEMBL1147307 | 0.89 | LIPE (0.59) | EPHX2LIPETP53MAPTSMN1; SMN2 | |
| SCHEMBL1146846 | 0.88 | KMT2A (0.50) | EPHX2LIPETP53MEN1KMT2A | |
| SCHEMBL15387686 | 0.87 | EPHX2 (0.53) | EPHX2LIPETP53MEN1MAPK1 | |
| SCHEMBL1147162 | 0.85 | HSD11B1 (0.46) | EPHX2TP53MAPT | |
| SCHEMBL1147254 | 0.84 | EPHX2 (0.65) | EPHX2LIPETP53MEN1MAPK1 | |
| SCHEMBL1147336 | 0.82 | LIPE (0.46) | EPHX2LIPEMEN1KMT2AEPHX1 | |
| SCHEMBL1146754 | 0.81 | EPHX2 (0.53) | EPHX2LIPETP53MEN1MAPK1 | |
| SCHEMBL12085011 | 0.80 | LIPE (0.58) | EPHX2LIPETP53MEN1MAPK1 | |
| SCHEMBL1146987 | 0.80 | MAPT (0.68) | EPHX2LIPETP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | claimed |
| WO-2011012602-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | claimed |
| US-8399676-B2 | Piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399676-B2 | Piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2011012602-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | ADRA1D, ADORA1, H1-0 | EPHX2 3415/4885LIPE 4188/4885TP53 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.